Method and compositions for preventing hormone induced adverse effects

A method of preventing adverse effects which may result from the administration of at least one hormone to a subject without detectable cancer comprising administering to said subject at least one carotenoid which does not exhibit substantial provitamin A activity in an amount of about 2 mg per day.

A method of preventing adverse effects which may result from the administration of at least one hormone to a subject without detectable cancer comprising administering to said subject at least one carotenoid selected from the group consisting of alpha-carotene, beta-carotene and cryptoxanthin in an amount of about 2 mg per day.

A method of preventing adverse effects which may result from the administration of at least one hormone selected from group consisting of estrogen, estradiol, estrone, medroxyprogesterone, norethindrone, norethisterone, norgestrel, progestin, and progesterone to a subject without detectable cancer comprising administering to said subject at least one carotenoid which does not exhibit substantial provitamin A activity in an amount from about 2 to about 10 mg per day without inhibiting the beneficial activity of said hormone.

A method of preventing adverse effects which may result from the administration of at least one hormone selected from the group consisting of estrogen, estradiol, estrone, medroxyprogesterone, norethindrone, norethisterone, norgestrel, progestin, and progesterone to a subject without detectable cancer comprising administering to said subject at least one carotenoid which does not exhibit substantial provitamin A activity in an amount from about 2 to about 6 mg per day without inhibiting the beneficial activity of said hormone.

A method of preventing adverse effects which may result from the administration of at least one hormone selected from the group consisting of estrogen, estradiol, estrone, medroxyprogesterone, norethindrone, norethisterone, norgestrel, progestin, and progesterone to a subject without detectable cancer comprising administering to said subject at least one carotenoid which does not exhibit substantial provitamin A activity in an amount of about 2 mg per day without inhibiting the beneficial activity of said hormone.

A method of preventing adverse effects which may result from the administration of at least one hormone selected from the group consisting of estrogen, estradiol, estrone, medroxyprogesterone, norethindrone, norethisterone, norgestrel, progestin, and progesterone to a subject without detectable cancer comprising administering to said subject at least one carotenoid selected from the group consisting of alpha-carotene and cryptoxanthin in an amount of about 2 mg per day without inhibiting the beneficial activity said hormone.

A unit dosage form suitable for administration to a human comprising a physiologically effective amount of at least one hormone selected from the group consisting of steroidal estrogen, estradiol, estrone, medroxyprogesterone, norethindrone, norethisterone, progestin, norgestrel, and progesterone, and at least one carotenoid wherein said carotenoid is in an amount effective to prevent the adverse effects which may result from the administration of said hormone.

A unit dosage form suitable for administration to a human comprising a physiologically effective amount of at least one hormone selected from the group consisting of steroidal estrogen, estradiol estrone, medroxyprogesterone, norethindrone, norethisterone, progestin, norgestrel and progesterone, and at least one carotenoid, wherein said carotenoid is in an amount effective to prevent the adverse effects which may result from the administration of said hormone without inhibiting the beneficial activity of said hormone.

A unit dosage form to any of clams 26 and 27 wherein said carotenoid is in an amount from about 2 to about 6 mg.

A unit dosage form suitable for once daily administration to a human comprising a physiologically effective amount of at least one hormone selected from the group consisting of steroidal estrogen, estradiol, estrone, medroxyprogesterone, norethindrone, norethisterone, progestin, norgestrel, and progesterone, and at least one carotenoid wherein said carotenoid is in an amount effective to prevent the adverse effects which may result from the administration of said hormone.

A unit dosage form suitable for once daily administration to a human comprising a physiologically effective amount of at least one hormone selected from the group consisting of steroidal estrogen, estradiol, estrone, medroxyprogesterone, norethindrone, norethisterone, progestin, norgestrel and progesterone, and at least one carotenoid, wherein said carotenoid is in an amount effective to prevent the adverse effects which may result from the administration of said hormone without inhibiting the beneficial activity of said hormone.

A unit dosage form suitable for once daily administration to a human comprising a physiologically effective amount of at least one hormone selected from the group consisting of steroidal estrogen, estradiol, estrone, medroxyprogesterone, norethindrone, norethisterone, progestin, norgestrel, and progesterone, and at least one carotenoid wherein said carotenoid is in an amount from about 2 to about 10 mg.

A unit dosage form suitable for once daily administration to a human comprising a physiologically effective amount of at least one hormone selected from the group consisting of steroidal estrogen, estradiol, estrone, medroxyprogesterone, norethindrone, norethisterone, progestin, norgestrel, and progesterone, and at least one carotenoid wherein said carotenoid is in an amount from about 2 to about 6 mg.

A unit dosage form suitable for once daily administration to a human comprising a physiologically effective amount of at least one hormone selected from the group consisting of steroidal estrogen, estradiol, estrone, medroxyprogesterone, norethindrone, norethisterone, progestin, norgestrel, and progesterone, and at least one carotenoid wherein said carotenoid is in an amount of about 2 mg.

A unit dosage form suitable for once daily administration to a human comprising a physiologically effective amount of at least one phytoestrogen and at least one carotenoid selected from the group consisting of zeta-carotene, phytoene, phytofluene, lutein, zeaxanthin, and astaxantine, wherein said carotenoid is in an amount of about 2 mg.

A unit dosage form suitable for once daily administration to a human comprising a physiologically effective amount of at least one phytoestrogen and at least one carotenoid selected from the group consisting of zeta-carotene, phytoene, phytofluene, lutein, zeaxanthin, and astaxantine, wherein said carotenoid is in an amount sufficient to cause effective serum concentrations of said carotenoid of up to about 1.5 μM.

A unit dosage form suitable for once daily administration to a human comprising a physiologically effective amount of at least one phytoestrogen and a mixture of lycopene and phytoene, wherein said mixture is in an amount of about 2 mg.

A unit dosage form suitable for once daily administration to a human comprising a physiologically effective amount of at least one phytoestrogen and a mixture of lycopene and phytofluene, wherein said mixture is in an amount of about 2 mg.

A unit dosage form suitable for once daily administration to a human comprising a physiologically effective amount of at least one phytoestrogen and a mixture of lycopene phytoene and phytofluene, wherein said mixture is in an amount of about 2 mg.

A unit dosage form suitable for once daily administration to a human comprising a physiologically effective amount of at least one phytoestrogen and at least one carotenoid selected from the group consisting of alpha-carotene and cryptoxanthin, wherein said carotenoid is in an amount of about 2 mg.